6.7.8.3. parp inhibitors mcrpc. far, two parp inhibitors monotherapy, olaparib rucaparib, licenced fda (ema approved olaparib) several parp inhibitors investigation approved combination arpi (see chapter 6.7.6.6; e.g., talazoparib, niraparib). randomised phase iii trial (profound) compared parp inhibitor olaparib alternative arpi mcrpc alterations ≥ 1 qualifying gene role hrr progression arpi. patients heavily pre-treated 1–2 chemotherapies 2 arpis . radiographic pfs blinded independent central review brca1/2 atm mutated population (cohort a) first endpoint significantly favoured olaparib (hr: 0.49, 95% ci: 0.38–0.63). final results os demonstrated significant improvement among men brca1/2 atm mutations (cohort a) (p = 0.0175; hr: 0.69, 95% ci: 0.50– 0.97). significant men (other) hrr alteration (cohort b) (hr: 0.96, 95% ci: 0.63–1.49). note, patients physician’s choice enzalutamide/abiraterone-arm progressed, 66% (n = 86/131) crossed olaparib. common aes anaemia (46.1% vs. 15.4%), nausea (41.4% vs. 19.2%), decreased appetite (30.1% vs. 17.7%) fatigue (26.2% vs. 20.8%) olaparib vs. enzalutamide/abiraterone. among patients receiving olaparib 16.4% discontinued treatment secondary aes, compared 8.5% patients receiving enzalutamide/abiraterone. interestingly, 4.3% patients receiving olaparib pulmonary embolism, compared 0.8% among receiving enzalutamide/abiraterone, none fatal. reports myelodysplastic syndrome acute myeloid leukaemia. first trial show benefit genetic testing precision medicine mcrpc. olaparib approval fda patients deleterious suspected deleterious germline- somatic hrr gene-mutated mcrpc, progressed following prior treatment enzalutamide abiraterone. ema approved olaparib patients brca1 brca2 alterations . recommended olaparib dose 600 mg daily (300 mg taken orally twice daily), without food. rucaparib approved fda patients deleterious brca mutations (germline and/or somatic) treated arpi taxane-based chemotherapy . approval based results single-arm triton2 trial (nct02952534). confirmed orr per independent radiology review 62 patients deleterious brca mutations 43.5% (95% ci: 31–57) . rucaparib second line arpi studied triton 3 trial discussed chapter 6.7.7.5 combination arpi plus parp inhibitor first-line mcrpc studied several rcts including aap plus olaparib , aap plus niraparib enzalutamide plus talazoparib . see table 6.7.2.